Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.44 |
| ▸ | CHRNG | P07510 | 3/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.44 |
| ▸ | CHRND | Q07001 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16854865 | 0.91 | CALCRL (0.54) | CALCRLSSTR3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23425577 | 0.82 | KLKB1 (0.45) | CALCRLSSTR3CHRNDHDAC4PLG | |
| SCHEMBL23230052 | 0.80 | CALCRL (0.60) | CALCRLSSTR3GRIA1 | |
| SCHEMBL14129702 | 0.79 | CPA1 (0.42) | SSTR3CTSLFOLH1SIRT2SIRT1 | |
| SCHEMBL19719375 | 0.79 | LTA4H (0.52) | CALCRLSSTR3PLG | |
| SCHEMBL14140557 | 0.79 | LTA4H (0.52) | CALCRLSSTR3PLG | |
| SCHEMBL23286081 | 0.78 | SSTR3 (0.53) | CALCRLSSTR3KDM1AMAOASIRT2 | |
| SCHEMBL12412728 | 0.77 | MMP1 (0.51) | CALCRL | |
| SCHEMBL15928006 | 0.75 | SSTR3 (0.44) | CALCRLSSTR3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL25083560 | 0.74 | SSTR3 (0.56) | CALCRLSSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458242-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | IMMUNOMEDICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150216997-A1 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity | IMMUNOMEDICS, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216997-A1 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity | CD74, CD2, CD22 | CALCRL 2838/4885SSTR3 942/4885CHRNA1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.